

# Improving Lives of People with Rare Diseases

---



For more information, please visit  
[www.paradigmtherapeutics.com](http://www.paradigmtherapeutics.com)



# Our Mission

Paradigm Therapeutics is dedicated to the development of SD-101 (Zorblesia™), which is an innovative whole body topical therapy for people living with the rare disease, Epidermolysis Bullosa (EB).

# A Late-Stage Rare Disease Company *Zorblisa*<sup>™</sup> (allantoin)



*Zorblisa*<sup>™</sup>  
(allantoin)



Singular focus on rare diseases with significant medical need

Initial disease focus, EB, as a whole-body topical treatment across all EB subtypes

Therapy being developed to allow treatment beginning at birth

Demonstrated in clinical trials robust efficacy and safety

Convenient once daily, topical administration

Zorblisa<sup>™</sup> positioned to be a whole-body skin treatment for all EB subtypes

Previous “Breakthrough Therapy Designation” in US

Orphan drug designations in US and EU

Small focused field sales force needed for specialty market

Proven team of development and scientific leaders

Deep and extensive relationships with EB experts and patient community

# Paradigm Therapeutics is Led by an Experienced Senior Management Team with Extensive Global Development Experience...



**Robert Ryan, PhD**  
Chief Executive Officer

Founder & CEO of Innova Therapeutics and Former Co-Founder and CEO of Scioderm. Former Managing Director of Celtic Pharma and Celtic Therapeutics




**Ronald V. Nardi, Ph.D.**  
EVP Development

35+ years experience in drug discovery/development and regulatory affairs, Operational and management R&D experience in large pharma organizations and small/medium sized companies including start-up/biotechnology firms



**Lisa Zimmerman**  
EVP of Regulatory Affairs, Compliance, and Quality

Ms. Zimmerman is an accomplished drug developer with over 35+ years of industry experience. Lisa is an accomplished professional with a proven track record of success in Clinical Operations, Regulatory Affairs, Quality Assurance, and Regulatory Compliance.



**Michael Zimmer, MBA**  
Chief Financial Officer

Highly experienced executive brings 30 years of experience as a business leader in various roles including Finance, Accounting, Operations, Supply Chain, Business and Employee Development



**Willistine Lenon**  
EVP Clinical Operations

Highly experienced Clinical Operations Executive with 29+ years in the field of clinical research, including senior roles at major CRO and pharmaceutical companies



**Steve Cole**  
Head of BD and Licensing

Highly experienced Business Development/Licensing executive with 40+ years of global industry experience.



# Epidermolysis Bullosa (EB)

“The worst disease you’ve never heard of<sup>1</sup>”



<sup>1</sup> DEBRA America

- **Epidermolysis Bullosa (EB) is a rare genetic disease of connective tissue, manifested by defective or deficient anchoring fibrils which provide structural support primarily in the skin**
- Manifested by defective or deficient anchoring fibrils - primarily in skin
- Characterized by extreme fragility of the skin
- Typically manifests at birth
- Disfiguring and very painful
- Mildest friction damages skin causing severe blistering and wound formation
  - Itching exacerbates wounds and healing
  - Wounds often become chronic; result in significant scarring
- Life altering; results in inability for patients to thrive
- Disease unknown until birth; can be fatal (typically due to sepsis)


# EB is an Orphan Disease in the U.S and E.U. and an Ultra-Orphan Disease in Japan

## Official estimates of prevalence are increasing as the disease becomes better understood

- **US: Est. 20,000 - 40,000 current cases (comparable to Cystic Fibrosis)**
  - Debra (Dystrophic Epidermolysis Bullosa Research Association of America) web site: 30,000
  - Stanford University EB web site: 25,000 – 50,000
  - EBMRF (EB Medical Research Foundation) – “Estimates indicate that as many as 100,000 Americans suffer from some form of EB.”
- **EU: Est. 50,000 to 80,000 current cases**
  - Gabriella Pohl-Gubo (5th International Conference on rare diseases-Krakow 2010)
  - Prevalence estimates in Northern Europe
    - Northern Ireland ~ 44/M (Covello et al. J INV DERM, 1998)
    - Scotland ~ 49/M (Horn et al. BRIT J DERM, 2008)
- **Japan: 1,000 – 5,000**
  - ~1,000 (Study Group for Rare Intractable Skin Diseases in 1994)
  - “at least 1,000 severe cases and likely thousands more” (Debra Japan)
- **Worldwide prevalence estimated at 500,000 patients**

# There are Three Main Subtypes of Epidermolysis Bullosa\*

## Skin structure



Source: Adapted from DEBRA America

## EB subtypes

Subtypes	Symptoms	Frequency	Mortality risk
<b>Simplex</b>	<ul style="list-style-type: none"> <li>➤ Blistering on hands and feet (localized)</li> <li>➤ Blistering all over body (generalized)</li> <li>➤ Contraction of joints</li> <li>➤ Fusion of fingers and toes</li> </ul>	~75%	
<b>Dystrophic</b>	<ul style="list-style-type: none"> <li>➤ Contraction of mouth membranes</li> <li>➤ Narrowing of esophagus</li> <li>➤ Possibility of skin cancer</li> </ul>	~20%	
<b>Junctional</b>	<ul style="list-style-type: none"> <li>➤ Marking and damage to skin or face</li> <li>➤ Internal blistering of oral tracts</li> <li>➤ Extensive blistering all over body</li> <li>➤ Blistering of membranes of internal organs</li> <li>➤ Severe complications can often become lethal</li> </ul>	~5%	

\*Kindler EB is a very rare 4<sup>th</sup> type of EB with about 250 affected individuals reported worldwide

# EB Patients Receive Care at Centers of Excellence...

There are comprehensive EB pediatric/adult clinics worldwide including a newly created EB clinic in Abu Dhabi



SEHA  
شركة أبوظبي للخدمات الصحية  
Abu Dhabi Health Services Co. P.J.S.C



COLUMBIA UNIVERSITY  
MEDICAL CENTER  
*Discover. Educate. Care. Lead.*



- There are a concentrated number of EB specialized research hospitals with large, identified patient populations
- DEBRA, the worldwide patient advocacy group, maintains large databases of patients

# Zorblesia™ Overview

## Zorblesia™ is Being Developed as Whole Skin Surface Topical EB Treatment for All Subtypes

- **Zorblesia™ is a proprietary new molecular entity (NME) which has completed Phase 2 and 3 development in the US and EU**
  - Demonstrated efficacy and excellent safety in Phase 2a, Phase 2b, and Phase 3 trials
  - **No systemic absorption, locally delivered**
  - Zorblesia™ previously received orphan designation for the US and EU, and would qualify in Japan **(10 years exclusivity)**
    - US data exclusivity for orphan designation will be for 7.5 years
    - Approved PIP in Europe - 12 years data exclusivity with defined registration path
    - No pathway for generic drugs for non-systemic therapeutics post expiration of exclusivity
  - Worldwide commercialization rights



# Commercially Viable Topical Formulation with Low Cost-of-Goods (COGS)

**There are several important attributes of the topical SD-101 therapy formulation including:**

- Ability to apply topical cream across the entire skin surface of EB patients, where defects in the skin resulting in blister and wound formation occur throughout the skin surface.
- Ease of Use: SD-101 is supplied as an emulsion cream supplied in a multi-use 8-ounce tube. There are no preparation requirements of the SD-101 cream.
- Fast dissolving emulsion cream with no need to rub into the skin surface
- Long term room temperature storage
- No special handling requirements or disposal requirements
- No systemic absorption, allantoin locally delivered linearly by dose across the various skin layers
  - A study was conducted in EB patients previously that were treated with SD-101 daily for a period of at least 1 year in addition to matched EB patients who were not on SD-101 therapy. Blood and urine samples were taken and assessed for allantoin concentrations. The study data indicated that allantoin is not systemically absorbed even under chronic usage in EB patients.

*12 key excipients needed to provide necessary attributes*

# Summary of Zorblesia™ Clinical Phase 2 and 3 Results Simplex, Junctional and Dystrophic EB Patients

# Summary of Zorblesia™ Clinical Development Program

Two Placebo Controlled Clinical Trials (SD-003 and SD-005) and 2 Open Label Extension Studies (SD-004 and SD-006)

## ➤ Two Placebo Controlled Clinical Trials with Similar Efficacy and Safety Results

- Total of 217 EB patients (Simplex, Dystrophic and Junctional) treated with 6% Zorblesia™

## ➤ Zorblesia™ is a topical whole-body treatment which has demonstrated in clinical trials clinically relevant safety and efficacy across all EB subtypes

### ▪ Rapid Target Wound Closure

- Proportion of patients with complete closure higher than placebo beginning at first visit (week 2) and continuing throughout trial in both studies
- Median time to complete wound healing in wounds that closed much faster in Zorblesia-treated patients versus patients on placebo

### ▪ Rapid Reduction in Whole Body Coverage in Lesional Skin and Wounds

- Phase 2 and 3 - Reduction in lesional skin (wounds and blisters) and whole body wound burden in Zorblesia-treated patients versus placebo patients in patients will all levels of wound burden at baseline

### ▪ Reduction in Skin Infection

- Phase 3 - The proportion of patients with skin infections was statistically significantly lower in the Zorblesia™ group versus the placebo group (18.3 versus 33.3%, P=0.026))

### ▪ Improvement in Itching within 7 Days of Zorblesia™ treatment versus placebo

- Recent survey in adults with either of the 3 major subtypes, 85% reported itch as the most troublesome symptom.<sup>1</sup>

<sup>1</sup>Papanikolaou M, Onoufriadis A, Mellerio JE, Nattkemper LA, Yosipovitch G, Steinhoff M, McGrath JA. Prevalence, pathophysiology and management of itch in epidermolysis bullosa. *Br J Dermatol*. 2021 May;184(5):10.1111/bjd.19496. Epub 2020 Nov 29. PMID: 32810291.

# Clearly Defined Registration Paths in US, EU, and Japan



- Agreements with FDA
  - Phase 3 registration plan
  - Approved primary endpoint
  - Preclinical, CMC requirements defined and completed
  - Treatment across all subtypes, ages 1 month and older



- Clinical program to support registration in Europe
  - PDCO agreed Pediatric Investigation Plan (PIP) – identical to US development plan
  - CMC and non-clinical programs agreed

# Opportunity to Benefit EB Patients in Multiple Markets

Topical whole skin surface treatment



Compelling efficacy data, rare pediatric and orphan designations provide rationale for access



Large commercial opportunity

- Therapy in development for EB targeting all subtypes
- Therapy in development for treating both pediatric and adult patients

- Compelling Phase 2a, Phase 2b, and Phase 3 efficacy data
- Orphan drug pricing
- Efficacy and safety benefits demonstrated in clinical trials for EB patients across all subtypes

- Topical EB treatment to treat whole body across all EB subtypes
- Specialty market of consolidated centers of EB excellence
- Small specialty sales force needed

## Prevalence of EB

- US 20,000–40,000
- EU 50,000–80,000
- ROW 300,000–400,000

